CH
Coherus Oncology, Inc.
CHRS · NASDAQ
$1.33 -3.48% (-$0.05)
1M +10.83%
Market Cap $211.7M
P/E Ratio -
Div. Yield -
ROE 181.73%
Bulios Fair Price
$1.69
27.1% upside
Trenutna cena
$1.33
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica CHRS trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
2/9Valuation
51 /100
Fair P/S 4.16x
P/B 3.48x
P/E N/A
Growth
0 /100
Declining Rev. growth 41.54%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 63.55%
Net margin 257.10%
Op. margin 307.44%
Quality
3 /100
Poor ROIC 135.38%
ROE 181.73%
ROA 68.50%
Debt
55 /100
Moderate Debt/Equity 0.62x
Current ratio 1.77x
Int. coverage -16.74x
Stability
25 /100
Unstable Beta 0.94x
Rev. volatility 56.75%
EPS volatility 435.47%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o CHRS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Dennis Lanfear
Employees
144
Headquarters
Redwood City
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report